No Tumor Suppressor Role for in Prostate Cancer.

To elucidate the pathogenesis of prostate diseases, following analysis, the gene was selected for further investigation. The gene has been associated with poor prognosis and is frequently mutated in different types of cancers. In this study, 50 benign prostatic hyperplasia (BPH) and 57 prostate cancer (PCa) tissues, including matched normal tissue for the patients, were analyzed by qRT-PCR and DNA sequencing for expression and the mutation profile, respectively. Expression of was increased in 60.7% of the PCa tissues compared with noncancerous tissue samples ( ≤ 0.001). However, expression was lower when compared with normal tissues in BPH ( = 0.920). Four coding sequence alterations were detected in BPH. Three silent mutations were located in codons 9, 32, and 275 and a missense mutation was observed in codon 384. Six alterations were identified in the intronic regions of the gene in both PCa and BPH. Five mutations were observed in both patient groups. A new alteration in intron 6 was observed in a patient with PCa. The gene may be associated with benign transformations rather than the tumors in prostate pathogenesis when its expression and mutation status are considered. However, the mechanism of in PCa needs further studies.